Back
45· Steady
Markets10h 16m ago
Nifty Pharma's June quarter earnings may decline due to fading gains from generic drug launches, with currency depreciation expected to offset some of the impact.
Archive Window: 7 Days Left
India
Who
Macquarie, Kunal Dhamesha, Dr. Reddy's, Biocon
What
Nifty Pharma's June quarter earnings may decline due to fading gains from generic drug launches, with currency depreciation expected to offset some of the impact.
When
Fri, 17 Jul 2026 00:00:00 GMT · 10h 16m ago
Where
India ·
Why
Currency depreciation and the absence of key generic product launches are expected to negatively impact earnings, although a stronger biologics pipeline for Biocon and future semaglutide opportunities offer some offset.
The Frontline Impact
How this affects you
The forecast suggests a potential downturn in earnings for India's pharmaceutical sector in the June quarter, influenced by currency fluctuations and shifts in generic product revenue streams.
Story chain
1 event in this threadNo related history yet - this is the origin event.